Can the New generation of perfusion technology compete or replace the conventional and widely preferred fed-batch technology?
15th November 2017 | 10am GMT, 11am CET, 3:30pm IST, CST 6am, 5am EST | Ankur Bhatnagar, Chief Scientific Manager of Biocon R&D |WATCH FOR FREE
Recently, there has been a renewed interest in the field of continuous processing. Some key factors driving this interest are – availability of better cell retention devices, improved cell lines and culture medium capable of supporting high cell densities.
These factors have contributed mainly in reducing the batch duration for making the required quantity of product, thus reducing the medium requirement and chances of batch failures significantly. With the continuous processing being considered as ‘back-in-the-game’, the question remains: Can the current perfusion technology compete or replace the conventional and widely preferred fed-batch technology?
Two cases are discussed to compare the performance features of fed-batch and perfusion processes. In both the cases, the product output from perfusion process is significantly higher (2 to 5 folds) than that from fed-batch, due to combination of factors like higher cell density, higher cell specific productivity, lower accumulation of toxic metabolites etc. These cases demonstrate the potential of perfusion process in significantly increasing the product output. However, there are certain challenges and points to be considered before a company decides to switch to a perfusion platform.
Presented by Ankur Bhatnagar, Chief Scientific Manager of Biocon R&D
Ankur is the Chief Scientific Manager & Head of Upstream Process Development at Biocon R&D. He has over 15 years of experience in Developing and Scaling up Upstream Processes using Mammalian, Yeast, Bacterial and Fungal platforms. In his current role, he leads the Upstream Mammalian and Microbial teams in the labs and pilot plants, to develop and Scale-up Processes at commercial scales. Ankur has extensive experience in forming & leading teams, setting up labs & pilot plants, Technology Transfers to various manufacturing sites, support regulatory filings etc.
Ankur has completed his masters in Biochemical Engineering & Biotechnology from I.I.T. (Indian Institute of Technology) Delhi. He also completed his Executive MBA from I.I.M. (Indian Institute of Management) Bangalore. He has served in past as the Board of Study member for BMS college, Bangalore and is currently serving as the Advisory Board member for the School of Biological Sciences at I.I.T. Delhi.
Sponsored by Repligen
Inspiring advances in bioprocessing, Repligen is a leader in pre-packed chromatography column technology, cell culture process intensification, single-use tangential flow filtration, and Protein A ligands development. Propelled by a culture of innovation and collaboration, and with a focus on cost and process efficiencies, our people and our technologies help meet critical bioproduction demands worldwide. Repligen bioprocessing solutions span clinical and commercial applications, used in over 10 commercial processes and over 100 Phase 1-3 processes. As the recognized global leader in Protein A manufacturing, Repligen Protein A affinity ligands are routinely used to purify most of the world’s monoclonal antibodies.
Named one of the fastest growing biotech companies in the USA, Repligen is headquartered in Boston, Massachusetts with manufacturing sites in Sweden, Germany and Massachusetts.
Presented by John Bonham-Carter of Repligen
A serial entrepreneur with experience in multiple countries in industries from newspapers to biotechnology. Within bioprocessing, he has worked with many different upstream technologies and most recently has propelled the XCellTM ATF System to become the industry leader in continuous culture equipment supply.
A regular international speaker on bioprocessing, SME entrepreneurship and business coaching.
Editor of “Continuous Bioprocessing, Current Practice & Future Potential”, available for free on www.continuous-bioprocessing.com.